Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from AngioDynamics ( (ANGO) ).
On February 3, 2026, AngioDynamics entered into a Transition and Retirement Agreement with President and CEO James C. Clemmer, confirming that he will remain in his role until a successor is appointed or until November 30, 2026, with the potential for month‑to‑month extensions. The agreement provides for continued vesting of Clemmer’s existing equity awards through his ultimate separation from service, after which his stock options and service-based restricted stock units will fully vest and his performance-based restricted stock units will remain eligible to vest according to their terms. In connection with this leadership transition, on January 30, 2026, the board approved retention agreements for the executive leadership team, granting cash retention awards tied to continued employment through six months after the new CEO’s start date or June 1, 2027, with key named executives eligible for awards equal to 150% of base salary and other leaders eligible for awards equal to 50% of base salary, underscoring the board’s focus on ensuring management stability during the CEO succession process.
The most recent analyst rating on (ANGO) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on AngioDynamics stock, see the ANGO Stock Forecast page.
Spark’s Take on ANGO Stock
According to Spark, TipRanks’ AI Analyst, ANGO is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative TTM cash flow) and bearish technicals (below major moving averages with negative MACD). These are partly offset by constructive earnings-call signals, including raised FY2026 revenue and adjusted EBITDA guidance and expectations for full-year cash-flow positivity, while valuation support is limited due to negative earnings and no dividend yield data.
To see Spark’s full report on ANGO stock, click here.
More about AngioDynamics
AngioDynamics, Inc. is a medical technology company focused on minimally invasive, image-guided medical devices used in vascular access, oncology, and peripheral vascular disease treatment, serving hospitals and specialty care providers in the healthcare sector.
Average Trading Volume: 590,109
Technical Sentiment Signal: Sell
Current Market Cap: $427M
Find detailed analytics on ANGO stock on TipRanks’ Stock Analysis page.